Skip to main content

Table 1 Baseline clinical characteristic of patients and controls

From: The relation between neutrophil-to-lymphocyte ratio and coronary chronic total occlusions

 

Control group (n = 75)

CAD group (n = 75)

CTO group (n = 75)

p

Age, years

58 ± 11

63 ± 10

61 ± 8

0.01

Male, n (%)

34 (45.3)

49 (65.3)

66 (88)

<0.001

Diabetes mellitus, n (%)

12 (16)

30 (40)

26 (34.7)

0.004

Hypertension, n(%)

50 (66.7)

55 (73.3)

49 (65.3)

0.52

Hyperlipidemia, n (%)

19 (25.3)

44 (58.7)

52 (69.3)

<0.001

Family history of CAD, n (%)

2 (2.7)

4 (5.3)

29 (38.7)

<0.001

Smoking, n (%)

25 (33.3)

33 (44.4)

39 (52)

0.06

Ejection fraction, %

57.9 ± 7.4

55.1 ± 10

51.3 ± 9.1

<0.001

Hemoglobin, g/dL

14.2 ± 1.6

13.8 ± 1.6

13.7 ± 1.7

0.16

Platelet, 103/ml

233 ± 61

251 ± 75

233 ± 68

0.17

WBC, 103/ml

7.40 ± 1.84

7.93 ± 1.96

8.63 ± 1.94

0.001

Neutrophil, 103/ml

4.16 ± 1.27

4.78 ± 1.36

5.62 ± 1.49

<0.001

Lymphocyte,103/ml

2.46 ± 0.76

2.33 ± 0.67

2.11 ± 0.72

0.01

NLR

1.79 ± 0.57

2.13 ± 0.64

2.95 ± 1.29

<0.001

Gensini score

1.5 (0-13)

26 (2-128)

64 (33.5-158)

<0.001

SYNTAX score

 

10.3 ± 6.8

19.2 ± 7.6

<0.001

  1. CAD, coronary artery disease; CTO, coronary total occlusion; NLR, neutrophil-to-lymphocyte ratio; WBC, white blood cell.
  2. Significant p values are bold.